Tag : CHRONIC MIGRAINE

CONFERENCE UPDATE

Reduced healthcare utilization and treatment escalation in chronic migraine with GLP-1 RAs
A real-world cohort study showed that GLP-1 RAs were associated with reduced healthcare utilization and lower treatment escalation among adults with chronic migraine compared with topiramate. GLP-1 RAs reduced emergency department visits, hospitalizations, triptan use, migraine-related procedures, and the need for additional preventive therapies, supporting a potential role in reducing migraine-related healthcare burden.
CONFERENCE UPDATE

Interim analysis of a long-term safety and efficacy extension study of atogepant in episodic and chronic migraine prevention
Atogepant is an oral anti-migraine drug that blocks the calcitonin gene-related peptide (CGRP) receptor.1 It was previously evaluated in the phase 3, randomized, double-blind, placebo-controlled trials ELEVATE and PROGRESS for the prevention of episodic migraine (EM) or chronic migraine (CM), respectively.
CONFERENCE UPDATE

Observational FINESSE study of real-world effectiveness and tolerability of fremanezumab in episodic and chronic migraine